

Publikationen

Originalartikel:

1. **R. Lehmann**, B. Leuzinger., F. Salomon
Symptomatic Hypoparathyroidism in Acquired Immunodeficiency Syndrome,
Horm. Res. 1994, 42, 295-299 (**IF: 1.730**)
2. **R. Lehmann**., Vokac A., Niedermann K., Agosti K., Spinass G.A.,
Loss of Abdominal Fat and Improvement of the Cardiovascular Risk Profile by Regular Moderate
Exercise Training in Non-Insulin-Dependent Diabetes mellitus
Diabetologia 1995, 38, 1313-1319 (**IF: 6.551**)
3. **R. Lehmann**., Borovicka J., Kunz P., Crelier G., Boesiger P., Fried M., Schwizer W.,
Spinass G.A.
Evaluation of Delayed Gastric Emptying in Diabetic Patients with Autonomic Neuropathy by a New MRI
Technique and Radio-opaque Markers.
Diabetes Care 1996, 18, 1075-1082 (**IF: 6.718**)
4. **R. Lehmann**, V. Kaplan, R. Bingisser, K. Bloch, G.A. Spinass
Impact of Increased Physical Activity on Cardiovascular Risk Factors in IDDM
Diabetes Care, 1997, 20, 1603-1611 (**IF: 6.718**)
5. E. Linetsky, R. Bottino, **R. Lehmann**, R. Alejandro, L. Inverardi, C. Ricordi
Improved human islet isolation using a new enzyme blend, Liberase
Diabetes 1997, 46, 1120 –1123 (**IF: 8.505**)
6. **R. Lehmann**, J.L. Wagner, L. A. Fernandez, J.J. Bourgoignie, C. Ricordi,
R. Alejandro, N.S. Kenyon
Effects of Ketamine Sedation on Glucose Clearance, Insulin Secretion and Counterregulatory Hormones
in Baboons (*Papio hamadryas*), J. Med. Primatol. 1997, 26, 312-21 (**IF: 1.107**)
7. R. Alejandro, **R. Lehmann**, C. Ricordi, N.S. Kenyon, M.C. Angelico, G. Burke, J. Nery, Shen S. Kong,
J. Miller, V. Esquenazi, A.E. Betancourt, Daniel H. Mintz
Long-Term Function (6 Years) of Islet Allograft in Type 1 Diabetes Mellitus,
Diabetes, 1997, 46, 1983-1989 (**IF: 8.505**)
8. P. Atkison, M. Chatzipetrou, A. Tsaroucha, **R. Lehmann**, A. Tsakis, D. Grant
Small bowel transplantation in children, Pediatr. Transplantation 1997: 1, 111-118 (**IF: 1.573**)
9. R. Alejandro, C. Ricordi, M.C. Angelico, J. Nery, M. Webb, L. Fernandez, **R. Lehmann**,
T. Karatzas, L. Olson, A.G. Tzakis
Donor Bone Marrow Infusions in Conjunction with Liver-islet Allograft Transplantation in Patients with Type 2
Diabetes, Transpl. Proc. 1997, 29, 745 (**IF 0.994**)
10. L. Fernandez, **R. Lehmann**, G. Selvaggi, S.S. Kong, R. Bottino, H. Li, E. Linetsky, N.S. Kenyon, R.
Alejandro, C. Ricordi
Influence of Variables on Canine Islet Isolation Results, Transpl. Proc. 1997, 29, 1950 (**IF 0.994**)
11. G. Selvaggi, L. Fernandez, R. Bottino, **R. Lehmann**, N.S. Kenyon, L. Inverardi, C. Ricordi
Improved Baboon Pancreatic Islet Cell Isolation, Transpl. Proc. 1997, 29, 1967-68 (**IF 0.994**)
12. L. A. Fernandez, R. Bottino, C. Ricordi, R. Oliver, **R. Lehmann**, M.F. Tsan, L. Inverardi
Endothelial Cell Dysfunction After Intraportal Islet Cell Transplant in Rats,
Transpl. Proc. 1997, 29, 2064-65 (**IF 0.994**)
13. R. Bottino, L.A. Fernandez, C. Ricordi, R. Oliver, **R. Lehmann**, M.F. Tsan, L. Inverardi
Transient Macrophage Inactivation Decreases the Occurrence of Early Islet Allograft Loss in Rodents,
Transpl. Proc. 1997, 29, 2057 (**IF 0.994**)
14. E. Linetsky, H. Li, L. Fernandez, R. Bottino, **R. Lehmann**, G. Selvaggi, S. Kong, C. Ricordi
Variables Affecting Human Vertebral Body Marrow Yields,
Transpl. Proc. 1997, 29, 1959 (**IF 0.994**)
15. R. Bottino, L. A. Fernandez, C. Ricordi, **R. Lehmann**, M. Fu Tsan, R. Oliver, L. Inverardi.
Transplantation of allogeneic islet of Langerhans in the liver effects of macrophage depletion on graft
survival and microenvironment activation, Diabetes 1998, 47, 316-23 (**IF: 9.019**)

16. E. Linetsky, **R. Lehmann**, H. Li, L. Fernandez, R. Botting, G. Selvaggi, R. Alejandro, C. Ricordi
Human Islet Isolation Using a New Enzyme Blend, *Transp. Proc.* 1997, 29, 1957-58 **(IF 0.994)**
17. **R. Lehmann**, L.A. Fernandez, R. Bottino, S. Szabo, C. Ricordi, R. Alejandro, N.S. Kenyon
Evaluation of Islet Isolation by a New Automated Method (Coulter® Multisizer IIe) and Manual Counting,
Transplant. Proc. 1998, 30, 373-74 **(IF 0.994)**
18. J. Borovicka, **R. Lehmann**, P. Kunz, F. Fraser, C. Kreiss, G. Crelier, P. Boesiger G.A. Spinass, M. Fried,
W. Schwizer. Evaluation of Gastric Emptying and Motility in Diabetic Gastroparesis with Magnetic
Resonance Imaging: Effects of Cisapride. *Am. J. Gastroenterol.* 1999; 94, 2866-73 **(IF 6.012)**
19. L.A. Fernandez, **R. Lehmann (two first authors)**, L. Luzi, A. Battezzati, A. Tzakis, C. Ricordi, R.
Alejandro
The effect of FK506 versus cyclosporine A on insulin sensitivity, acute insulin response, and lipid
metabolism *Transplantation* 1999; 68 (10), 1432-41. Correction: *Transplantation* 2000; 69, 1027 **(IF
3.498)**
20. N.S. Kenyon, L.A. Fernandez, **R. Lehmann (two second authors)**, M. Masetti, A. Ranuncoli, M.
Chatzipetrou, G. Iaria, D. Han, J. Wagner, Ph. Ruiz, M. Berho, L. Inverardi, R. Alejandro, D.H. Mintz, , A.
D. Kirk, D. M. Harlan, L. Burkly, C. Ricordi
Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-
CD154
Diabetes 1999; 48, 1473-81 **(IF: 8.505)**
21. D. Perucchini, U. Fischer, G.A. Spinass, A. Huch, R. Huch, **R. Lehmann**
Fasting plasma glucose to screen for gestational diabetes mellitus: A population based study
Brit. Med. J. 1999; 318, 812-15 **(IF: 13.660)**
22. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results
of the HOPE study and MICRO-HOPE substudy
Lancet 2000, 355: 252-59 (Investigator) **(IF: 30.758)**
23. Effects of an angiotensin-converting –enzyme inhibitor, ramipril, on cardiovascular events in high-risk
patients. The Heart Outcomes Prevention Evaluation Study Investigators
N Engl J Med 2000, 342: 145-153 (Investigator) **(IF: 47.050)**
24. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators
N Engl J Med 2000, 342: 154-160 (Investigator) **(IF: 47.050)**
25. **R. Lehmann**, H. Engler, R. Honegger, W. Riesen, G.A. Spinass
Alterations of Lypolytic Enzymes and High-Density Lipoprotein Subfractions Induced by Physical Activity in
Type 2 Diabetes Mellitus
Eur. J. Clin. Invest. 2001; 31: 37-41 **(IF: 2.643)**
26. **R. Lehmann**, S. Kayrooz, H. Greuter, G.A. Spinass
Clinical and Technical Evaluation of a New Self-Monitoring Blood Glucose Meter: Assessment of
Analytical and User Error
Diabetes Res. Clin. Pr. 2001; 53: 121-128 **(IF: 2.160)**
27. M. Brändle, Th. Pfammatter, G.A. Spinass, **R. Lehmann**, Ch. Schmid
Assessment of Seletive Arterial Calcium Stimulation and Hepatic Venous Sampling to Localize Insulin-
Secreting Tumors
Clin. Endocrinology 2001; 54:1-7 **(IF: 3.201)**
28. M. Brändle, **R. Lehmann**, F.E. Maly, C. Schmid, G.A. Spinass
Diminished insulin secretory response to glucose but normal insulin and glucagon secretory response to
arginine in a family with maternally inherited diabetes and deafness to to mitochondrial tRNA^{LEU(UUR)}
gene mutation *Diabetes Care* 2001; 24, 1253-58 **(IF: 6.718)**
29. K. Maedler, G.A. Spinass, **R. Lehmann**, P. Sergeev, M. Weber, A. Fontana, N. Kaiser, M.Y. Donath
Glucose induces beta-cell apoptosis via up-regulation of the FAS-Receptor in human islets: a link

between type 1 and type 2 diabetes
Diabetes 2001; 50: 1683-90 (IF: 8.505)

30. W. Moritz, F. Meier, D. Stroka, M. Giuliani, P. Kugelmeier, Ph. Nett, **R. Lehmann**, D. Candinas, M. Gassmann, W. Weber
Apoptosis in hypoxic human pancreatic islets correlates with HIF-1 α expression
Fexp FASEB J. 2002; 16:745-7 (IF: 6.401)
31. P. Wiesli, M. Brändle, B. Schwegler, **R. Lehmann**, G.A. Spinas, C. Schmid
Low plasma glucose level is not an appropriate criterion to end the 72-hour fast in the evaluation for hypoglycemic disorders
J Int Med 2002; 252: 504-9 (IF: 5.942)
32. K. Maedler, A. Fontana, F. Ris, P. Sergeev, Ch. Toso, J. Oberholzer, **R. Lehmann**, F. Bachmann, A. Tassinato, G.A. Spinas, Ph.A. Halban, M.Y. Donath
FLIP switches Fas-mediated glucose signaling in human pancreatic beta-cells from apoptosis to cell replication
PNAS 2002; 99: 8236-41 (IF: 9.432)
33. **R. Lehmann**, R.A. Honegger, Ch. Feinle, M. Fried, G.A. Spinas, W. Schwizer
Long-term effect of cisapride on gastric emptying and glucose control in patients with diabetes mellitus and gastroparesis: a double-blind, placebo-controlled, cross-over-study
Exp Clin Endocr Diabet 2003; 111: 255-61 (IF: 1.685)
34. **R. Lehmann**, M. Weber, A. Berchtold, R. Züllig, T. Pfammatter, W. Moritz, K. Mädler, M. Donath, P. Ambühl, N. Demartines, P.A. Clavien, G.A. Spinas
Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: Two-year follow-up
Amer J Transpl 2004; 4, 1117-21 (IF: 6.443)
35. S. Mohanty, G.A. Spinas, K. Maedler, R.A. Züllig, **R. Lehmann**, M.Y. Donath, T. Trüb
Overexpression of IRS2 in isolated pancreatic islets causes proliferation and protects human beta-cells from hyperglycemia-induced apoptosis
Exp Cell Res 2005;3003:68-78 (IF 3.589)
36. M. Giuliani, W. Moritz, E. Bodmer, D. Dindo, P. Kugelmeier, **R. Lehmann**, M. Gassmann, P. Groscurth, M. Weber
Central necrosis in isolated hypoxic human pancreatic islets: Evidence for post-isolation ischemia
Cell Transplantation 2005; 14: 67-76 (IF 5.126)
37. J. Storling, J. Binzer, A.K. Andersson, R.A. Züllig, M. Tonnesen, R. Lehmann, G.A. Spinas, S. Sandler, N. Billestrup, T. Mandrup-Poulsen
Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt
Diabetologia 2005; 48: 2039-2050 (IF: 6.551)
38. I. Aeberli, L. Molinari, G. Spinas, **R. Lehmann**, D. l'Allemand, M. B. Zimmermann
Dietary intakes of fat and antioxidant vitamins are predictors of subclinical inflammation in overweight Swiss children
Am. J. Clin. Nutr. 2006; 84: 748-55 (IF 6.307)
39. P.Wiesli, **R. Lehmann**, PA. Krayenbuehl, C. Schmid, G. A. Spinas
Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus
Exp. Clin. Endocr. Diab. 2006;114:539-43 (IF: 1.685)
40. A. J. Flammer, F. Hermann, P. Wiesli, B. Schwegler, R. Chenevard, D.Hürlimann, I. Sudano, St. Gay, W. Riesen, F. Ruschitzka, T. F. Lüscher, G. Noll, **R. Lehmann**
Effect of losartan, compared to atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension,
Hypertension 2007, 25:785-791 (IF: 6.614)

41. **R. Lehmann**, R. A. Zuellig, P. Kugelmeier, A. Perren, Ph. Baenninger, W. Moritz, M. Weber, G. A. Spinas
Superiority of Small Islets in Human Islet Transplantation
Diabetes 2007; 56: 594-603 (IF: 8.505)
42. B. Ledergerber, HJ Furrer, M. Rickenbach, **R. Lehmann**, L. Elzi, B. Hirschel, M. Cavassini, E. Bernasconi, P. Schmid, M. Egger, R. Weber
Factors Associated with the Incidence of Diabetes mellitus Type 2 in HIV-infected Participants of the Swiss HIV Cohort Study
Clin Inf Dis 2007; 45: 111-9 (IF: 8.195)
43. G. Cavallari, R.A. Zuellig, **R. Lehmann**, M. Weber, W. Moritz
Rat pancreatic islet size standarization by the „hanging drop” technique
Transp. Proc. 2007; 39: 2018-2020 (IF 0.994)
44. I. Aeberli, M. B. Zimmermann, L.Molinari, **R. Lehmann**, D. l'Allemand, G. A. Spinas, K. Berneis
Fructose intake is a predictor of LDL particle size in overweight schoolchildren
Amer. J. Clin. Nutr. 2007; 86: 1174-8 (IF 6.562)
45. I. Aeberli, R. Biebinger, **R. Lehmann**, D. l'Allemand, G. A. Spinas, M. B. Zimmermann
Serum retinol-binding protein 4 concentrations and ist ratio to serum retinol are associated with obesity and metabolic syndrome components in children
J. Clin. Endocrinol. Metab. 2007, 92: 4359-65 (IF: 6.201)
46. P. A. Gerber, V. Pavlicek, R. Zuellig, T. Pfammatter, R. Wuethrich, P.A. Clavien, M. Weber, G. A. Spinas, N. Demartines, **R. Lehmann**
Simultaneous islet-kidney transplantation versus pancreas-kidney transplantation in type 1 diabetes mellitus: A five year singe centre follow-up
Diabetologia 2008; 51: 110-119 (IF: 6.551)
47. P.A. Krayenbuehl, P. Wiesli, Ch. Schmid, **R. Lehmann**, G.A. Spinas, K. Berneis
Insulin sensitivity in type 2 diabetes is associated with LDL particle size more closely than with triglycerides and HDL-cholesterol
Swiss Medical Weekly, 2008; 138: 275-80 (IF 1.681)
48. **R. Lehmann**, G.A. Spinas, W. Moritz, M. Weber
Has time come for new goals in islet transplantation
Am. J. Transplant. 2008; 8: 1096-1100 (IF: 6.443)
49. Greenbaum, Carla; Mandrup-Poulson, Thomas; McGee, Paula; Battelino, Tadej; Haastert, Burkhard; Ludvigsson, Johnny; Lachin; John M; Pozzili, Paolo; Kolb, Hubert The Type 1 Diabetes TrialNet Research Group and the European C-Peptide Trial Study Group (**Coauthor**)
Randomized Comparisons of the Mixed Meal Tolerance Test versus the Glucagon Stimulation Test for the Assessment of Beta Cell Function in Type 1 Diabetes
Diabetes Care 2008: 31; 1966-71 (IF: 6.718)
50. P. Kugelmeier, Ph. Nett, R. Zuellig, **R. Lehmann**, M. Weber, W. Moritz
Expression and hypoxic regulation of the endothelin system in endocrine cells of human and rat pancreatic islets
Pancreas 2008; 9: 133-149 (IF: 2.773)
51. I. Aeberli, N.Beljean, **R. Lehmann**, D. l'Allemand, G. Spinas, M. B. Zimmermann
The fatty acid binding protein aP2 is increased in overerweight children and interacts with dietary fat and saturated fat intake to predict measures of subclinical inflammation and insulin resistance
International J Obesity 2008:32: 1513-20 (IF: 4.343)
52. I. Aeberli, G.A. Spinas, **R. Lehmann**, D. L'Allmand, L. Molinari, M.B. Zimmermann
Diet determines features of the metabolic syndrome in 6- to 14-year-old children
Int. J. Vitam. Nutr. Res. 2009; 79: 14-23 (IF: 0.897)

53. N.J. Mueller, M. Weisser, T. Fehr, RP Wühtrich, B. Müllhaupt, **R. Lehmann**, A. Imhof, J.D. Aubert, M. Genoni, R. Kunz, M. Weber, J. Steiger
Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor
Transp. Infect. Dis. 2009, Oct. 5 (Epub ahead of print) **(IF: 2.063)**
54. H. Uthoff, **R. Lehmann**, M. Sprenger, P. Wiesli
Skipping meals or carbohydrate free meals in order to determine basal insulin requirement in subjects with type 1 diabetes mellitus
Exp Clin Endocrinol Diabetes 2010; 118; 325-27 **(IF: 1.685)**
55. G. Schernthaner, A.H. Barnett, D.J. Betteridge, R. Carmena, A. Ceriello, B. Charbonnel, M. Hanefeld, **R. Lehmann**, M.T. Malecki, R. Nesto, V. Pirags, A. Scheen, A. Sjöholm, A. Tsatsoulis, R. De Fronzo
Is the ADA/EASD algorithm for the management of type 2 Diabetes (January 2009) based on evidence or opinion? A critical analysis
Diabetologia 2010, 53: published online: 31 March 2010 **(IF: 6.551)**
56. F. Item, S. Heinzer-Schweizer, M. Wyss, P. Fontana, **R. Lehmann**, A. Henning, M. Weber, P. Boesiger, U. Boutellier, M. Toigo
Mitochondrial capacity is affected by glycaemic status in young untrained women with type 1 diabetes but is not impaired relative to healthy untrained women
Am J Physiol Regul Integr Comp Physiol 301:R60-R66, 2011 **(IF: 4.395)**
57. P.A. Gerber, D. Spirk, M. Brandle, **R. Lehmann**, U. Keller
Regional intercultural differences influence glycaemic control in patients with type 2 diabetes mellitus in Switzerland
Swiss Med Wkly. 2011;141:w13218 **(IF: 1.823)**
58. C. Danzer, K. Eckhardt, A. Schmidt, N. Fankhauser, S. Ribrioux, B. Wollscheid, L. Müller, R. Schiess, R.A. Zuellig, **R. Lehmann**, G.A. Spinas, R. Aebersold, Ruedi, W. Krek
A comprehensive description of the N-glycoproteome of mouse pancreatic β -cells and human islets
J. Proteome Res. 2012; 11: 1598-1608 **(IF 5.460)**
59. A. Zanchi, **R. Lehmann**, J. Philippe
Antidiabetic Drugs and Kidney Disease
Swiss Medical Weekly 2012; 142: w13629 **(IF: 1.895)**
60. P.A. Gerber, R. Locher, B. Schmid, G.A. Spinas, **R. Lehmann**
Smoking is associated with impaired long-term glucose metabolism in patients with type 1 diabetes mellitus Nutr Metab Cardiovas 2013, 23: 102-108 **(IF: 3.438)**
61. R.A. Zuellig, G. Cavallari, P. Gerber, O. Tschopp, G.A. Spinas, W. Moritz, **R. Lehmann**
Improved physiological properties of gravity-enforced reassembled rat and human pancreatic pseudoislets
Journal of Tissue Engineering and Regenerative Medicine (online 2014) **(IF: 4.428)** DOI: 10.1002/term.1891
62. **Lehmann R.**, Graziano J., Brockmann J., Pfammatter Th., Kron Ph., de Rougemont O., Mueller T., Zuellig RA, Spinas GA, Gerber PA
Glycemic control in simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: A prospective 13 year follow-up
Diabetes Care 2015, 38:752-59 **(IF: 8.570)**
63. Riebenfeld D., Spirk D., Mathis A., Villiger L., Gerber PA, Gasser UE, **Lehmann R.**
Treatment Intensification by Insulin Glargine in Patients with Inadequately Controlled Type 2 Diabetes Improves Glycemic Control with a high Treatment Satisfaction and no Weight Gain
Swiss Med Wkly. 2015;145:w14114 **(IF: 1.877)**
64. Gerber P.A., Locher R., Züllig R.A., Tschopp O., Ajdler-Schäfler E., Kron Ph., C. Oberkofler, Braendle M., Spinas G.A., **Lehmann R.**
Glycemia, hypoglycemia and costs of simultaneous islet-kidney or islet after kidney transplantation versus intensive insulin therapy
Transplantation 2015;99: 2174–2180 **(IF: 3.781)**
65. Pratik Choudhary*, Michael R. Rickels*, Peter A. Senior*, Marie-Christine Vantyghem*, Paola Maffi, Thomas W. Kay, Bart Keymeulen, Nobuya Inagaki, Frantisek Saudek F, **Roger Lehmann**^{#1} (co-senior author), Bernhard J. Hering[#] (co-senior author)
Evidence-based treatment of type 1 diabetes complicated by problematic hypoglycemia: A

comprehensive algorithm comprising educational, technological, and transplant interventions
Diabetes Care 2015;38:1016–1029 (IF: 8.570)

66. Dietrich, MB, Zuellig RA, Spinass GA, **Lehmann R**, Tschopp O, Niessen M
Specific and redundant roles of PKB α /AKT1 and PKB β /AKT2 in human pancreatic islets
Experimental Cell Research 2015;338:82-88 (IF: 3.372)
67. Hochuli M, Christ E., Meienberg F., **Lehmann R.**, Krützfeld J., Baumgartner M.R.
Alternative night-time nutrition regimens in glycogen storage disease type I: a controlled crossover study
J Inher Metab Dis. 2015 Nov;38(6):1093-8 (IF: 4.138)
68. Lina Quteineh L, Bochud PY, Golshayan D, Crettol S, Venetz JP, Oriol M, Kutalik Z, Treyer A, **Lehmann R**, Mueller NJ, Binet I, Van Delden Ch, Steiger J, Mohacsi P, Dufour JF, Soccacal PM, Pascual M, Eap CB
and the Swiss Transplant Cohort Study
CR2C2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with organ transplantation
The Pharmacogenomics Journal , (8 December 2015) | doi:10.1038/tpj.2015.82 (IF: 5.513)
69. Gerber, PA, Hochuli M, Benediktsdottir, Bara D., Zuellig RA, Tschopp O, Glenk M, de Rougement O, Oberkofler Ch, Spinass GA, **Lehmann R**.
Islet transplantation as safe and efficacious method to restore glycemic control and to avoid severe hypoglycemia after donor organ failure in pancreas transplantation
Clinical Transplantation 2018, 32 (1), e13153 (IF:1.80)
70. M. Brändle, P. Diem, **R. Lehmann**, C. Stettler, G. Faber Heneimann, L. Einehmann
SMBG bei Patienten mit Typ-2-Diabetes ohne Insulintherapie: Fokus auf relevante Studien
Diabetes Stoffwechsel Herz, 2017, 26; online
71. Guntram Schernthaner; **Roger Lehmann**; Martin Prázný; Leszek Czupryniak; Kristine Ducena; Peter Fasching, Andrej Janež; Avraham Karasik; Peter Kempler⁹ Emil Martinka; Marina V Shestakova; Lea Smirčić Duvnjak and Tsvetalina Tankova
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
Cardiovascular Diabetology 2017, Oct 23;16(1):137
72. Katrin E Schimke, Frida Renström, Sandro Meier, Christoph Stettler, Michael Brändle, and the SwissDiab Study Group
Compliance with guidelines for disease management in diabetes: results from the SwissDiab Registry
BMJ open Diabetes Research and Care 2018, 6:
73. Neofytos D, Chatzis O, Nasioudis D, Janke EB, Lecompte TD, Garzoni C, Berger C, Cussini A, Boggian K, Khanna N, Manuel O, Mueller NJ, van Delden C Swiss Transplant Cohort study, Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipient in the Swiss Transplant Cohort Study. *Transpl Infect Dis*, 2018, 20 e12898
74. Michael R. Rickels, Peter G. Stock, Eelco J. P. de Koning, Lorenzo Piemonti, Johann Pratschke, Rodolfo Alejandro, Melena D. Bellin, Thierry Berney, Pratik Choudhary, Paul R. Johnson, Raja Kandaswamy, Thomas W. H. Kay, MBBS, Bart Keymeulen, Yogish C. Kudva, Esther Latres, Robert M. Langer, **Roger Lehmann**, Barbara Ludwig, James F. Markmann, Marjana Marinac, Jon S. Odorico, François Pattou, Peter A. Senior, James A. M. Shaw, Marie-Christine Vantyghem, and Steven White
Defining Outcomes for β -Cell Replacement Therapy in the Treatment of Diabetes: a Consensus Report on the Igls Criteria from the IPITA/EPITA Opinion Leaders Workshop
Transplant Int 2018, 31:343-52
75. Lina Quteineh, Wójtowicz Agnieszka, Pierre-Yves Bochud, Severine Crettol, Jean-Pierre Venetz, Oriol Manuel, Dela Golshayan, **Roger Lehmann**, Nicolas J Mueller, Isabelle Binet, Christian van Delden, Jürg Steiger, Paul Mohacsi, Jean-francois Dufour, Paola M. Soccacal, Zoltan Kutalik, Gerard Waeber, Peter Vollenweider, Mike Recher, Christoph Hess, Armin von Gunten, Philippe Conus, Manuel Pascual, Chin B Eap and the Swiss Transplant Cohort Study
Genetic inflammatory markers associated with diabetes in solid organ transplant recipients
American J Transpl 2019 Jan;19(1):238-246

76. K. Hatz, A. Elisabeth Minder, **R. Lehmann (common first authors)**, T. Drescher, B. Gerendas, U. Schmidt-Erfurth, A. Kaider, C. Prunte, H. Zulewski, The prevalence of retinopathy in patients with type 1 diabetes treated with education-based intensified insulin therapy and its association with parameters of glucose control, *Diabetes Research and Clinical Practice* 2019;148:234-9
77. Hochuli M, Gerber Ph, E. Ajdler-Schäfler, R.A. Züllig, G.A. Spinaz, **R. Lehmann**
Achievement of good long-term glycemic control after islet transplantation: single or multiple initial islet transplantation?
Am J Transpl (in preparation)
78. Bianca S. Gerendas, Katja Hatz, Alexandra Kaider, Henryk Zulewski, **Roger Lehmann**, Alessio Montuoro, Christian Prunte, Ursula Schmidt-Erfurth
Ganglion cell layer thickening in well-controlled patients with type 1 diabetes: an early sign for diabetic retinopathy?
Acta Ophthalmologica, 2020, 98:e292-300
79. Harris S, Abrahamson MJ, Ceriello A, Charpentier G, Evans M, Lehmann R, Liebl A, Linjawi S, Holt RIG, Hosszufalusi N, Rutten G, Vilsboll T
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in people with type 2 diabetes
Drugs 2020; 80:147-165
80. Robinson M, Lehmann R
Practical use of insulin degludec/insulin aspart (IDegAsp) in a multinational setting: beyond the guidelines
DOM 2020 in press

Uebersichtsartikel

1. **Lehmann R.**, Ist Kuhmilch am Typ I Diabetes schuld? (Is Cow's Milk Exposure Responsible for Type 1 Diabetes Mellitus), D-Journal 1993, 105, 6-9
2. **Lehmann R.**, Spinas G.A.,
Abklärungen von Hypoglykämien (Evaluation of Hypoglycemias)
Schw. Med. Wochenschr. 1994, 124, 1155-1161
3. **Lehmann R.**, Spinas G.A.,
Ist eine Prävention von Diabetes mellitus möglich? (Is a Prevention of Diabetes mellitus possible?)
Therap. Umschau 1994, 51, 693-700
4. **Lehmann R.**, Spinas G.A.,
Diabetische Nephropathie: Bedeutung der Mikroalbuminurie und Proteinurie beim Typ-I und Typ-II Diabetes mellitus (Diabetic Nephropathy: Significance of Micro- and Albuminuria in IDDM and NIDDM Patients).
Schweiz. Rundschau für Medizin (Praxis), 1995, 84 (44), 1265-1271
5. **Lehmann R.**, Spinas G.A.,
Die Rolle der körperlichen Aktivität in der Therapie und für die Prävention des Typ 2 Diabetes mellitus (Benefits of physical activity in the management and prevention of non-insulin dependent diabetes mellitus)
Therap. Umschau, 1996, 53, 925-933
6. **Lehmann R.**, Spinas G.A.,
Diabetic Gastroparesis, Dialogue, 1997, 2, 11-16
7. **Lehmann R.**
Inseltransplantation. Neue Perspektiven für eine alte Herausforderung (Islet transplantation: new perspectives for an old challenge). D-Journal, 1997, 129, 20-26
8. **Lehmann R.**
Effects of physical activity on cardiovascular risk factors in type 2 diabetes mellitus
Practical Diabetes International, 1998, 15, 151-156
9. **Lehmann R.**
Which form of therapy (insulin therapy or oral antidiabetics) is best for a patient with newly diagnosed type 2 diabetes mellitus. Schweiz-Rundsch-Med-Prax. 1998; 87(41): 1368-9
10. Wiesli P., **Lehmann R.**
Pifalls in the evaluation of spontaneous hyperinsulinemic hypoglycemia. Diabetes Spectrum 2000, 13: 56-59
11. **Lehmann R.**
Gestational diabetes (Schwangerschaftsdiabetes), D-Journal, 2000; 143: 6-11
12. **Lehmann R.**, Spinas G.A.
Screening, diagnosis, and management of diabetes mellitus and diabetic complications
Therap. Umschau, 2000, 57, 12-21
13. **Lehmann R.**
Is type 1 diabetes cured? (Ist der Typ-1 Diabetes mellitus 1 besiegt)?, D-Journal 2000;146: 14-16
14. **Lehmann R.**
Die Bedeutung der postprandialen Hyperglykämie
Schweiz. Rundschau für Medizin (Praxis), 2001; 90: 345-8
15. **R. Lehmann**, M. Brändle
Diagnosis and management of gestational diabetes
Schweiz. Med. Forum, 2001; 20: 526-31
16. G.A. Spinas, **R. Lehmann**
Diabetes mellitus: Diagnosis, classification, and pathogenesis
Schweiz. Med. Forum, 2001; 20: 519-25
17. M. Brändle, **R. Lehmann**, G.A. Spinas
Epidemiology, diagnosis, and prophylaxis of coronary heart disease in type 2 diabetes mellitus
Schweiz. Med. Forum, 2001; 20: 545-49

18. B. Schwegler, T. Böni, J. Furrer, G.A. Spinas, **R. Lehmann**
Management of the diabetic foot (Praktisches Management des diabetischen Fusses)
Therap. Umschau 2002; 59: 435-42
19. **R. Lehmann**
Towards a new approach to lipid disorders in diabetes: The Heart Protection Study
Diabetes Voice 2002; 47: 34-38
20. **R. Lehmann** for the Metabolic syndrome working group: Diagnosis, and Treatment of the Metabolic
Syndrom, Swiss Medical Forum October 2004
21. **R. Lehmann**, G.A. Spinas:
Diagnose und Pathogenese des Diabetes mellitus Typ 2 (Diagnosis and pathogenesis of type 2 Diabetes
mellitus)
Schweiz. Med. Forum 2005; 5;968-75
22. **R. Lehmann**, V. Pavlicek, G.A. Spinas, M. Weber
Inseltransplantation bei Typ 1 Diabetes mellitus
Therapeutische Umschau 2005; 62: 481-86
23. **R. Lehmann**
Ab wann ist Ihr Patient ein Diabetes-Patient?
Hausarzt Praxis – Fortschritte in der Medizin 2006; 5: 11-15
24. V.Pavlicek, **R. Lehmann**
Funktionelle Insulintherapie (FIT) beim Typ-1-Diabetes
Der Diabetologe, 2006; 2: 314-20
25. N. Kamber, **R. Lehmann**
Posttransplantations-Diabetes mellitus: Eine neue Entität?
Cardiovasc 2008, 7; No. 1: 14-19
26. Ph. A. Gerber, G.A. Spinas, **R. Lehmann**
Continuous glucose monitoring in type 1 diabetes mellitus after beta cell replacement therapy
Infusystems International 2008, 7: 21-24
27. Ph. A. Gerber, **R. Lehmann**
Metabolisches Syndrom: Mehr körperliche Aktivität mit gezieltem Förderungsprogramm
Cardiovasc 2008, 7; No.4: 35-37
28. **R. Lehmann**, A. Troendle, M. Brändle
New insights into diagnosis and management of gestational diabetes mellitus: Recommendations of the
Swiss Society for Endocrinology and Diabetes
Ther Umsch. 2009, 66: 695-706
29. Henzen C, Christ E, Elsässer P, Fischer-Taeschler D, Diem P, Wiesli P, Meier CA, Schönle E, **Lehmann
R.**
Erhöhtes Krebsrisiko durch Insulin Glargin (Lantus®)?
Swiss Medical Forum 2009; 9: 755-6
30. **R. Lehmann**
Das Glukosegedächtnis meldet sich zurück
Swiss Med Forum, 2009, 09(21) : 398-401
31. **R. Lehmann**
Schwangerschaftdiabetes und Diabetes in der Schwangerschaft
D-Journal, 2010, 205; 24-28
32. R. Seeger, **R. Lehmann**
Fahreignung und Fahrfähigkeit bei Diabetes mellitus
Ther Umsch. 2011; 68: 249-52
33. **R. Lehmann**, Ph. Gerber
Der nierenkranke Patient mit Typ 1 Diabetes mellitus: Nierentransplantation allein oder mit Insel- oder
Pankreastransplantation? (End-stage Nephropathy in Type 1 Diabetes Mellitus: Kidney Transplantation
alone or combined with Islet or Pancreas Transplantation?)
Ther Umsch., 2011; 68: 699-705

34. K. Hauser, D. Franzen, **R. Lehmann**
Gestationsdiabetes
Praxis 2012; 101:1347-57
35. **R. Lehmann**, Ch. Henzen, E. Christ
Neue Richtlinien der SGED/SSED zur Therapie des Typ 2 Diabetes mellitus
info@herz+gefäss 2013; 4:20-24
36. **R. Lehmann**
Fahrtüchtigkeit bei Diabetes mellitus
info@herz+gefäss 2013; 3:12-16
37. **R. Lehmann**
Editorial: Aktuelle Diabetes Therapie: Immer mehr Behandlungskombinationen
info@herz+gefäss 2013; 4:1-3
38. **R. Lehmann**
Degludec ein neues langsam wirkendes Insulin
info@herz+Gefäss 2014, 4: 12-14
39. **Bucher St, Pavlicek V, Lehmann R.**
Zeitgemässe Therapie des Diabetes Typ 2 und zukünftige Ansätze
Swiss Medical Forum 2015
40. **R. Lehmann**
Wie moderne Technologie die Diabetes-Behandlung verbessert
Schw. Aerztezeitung 2017; 98:1278-9
41. **R. Lehmann**
Technologie bei der Behandlung des Diabetes mellitus Typ 1:
Ersetzt das künstliche Pankreas das traditionelle Basis-Bolus-System?
Diabetes Stoffwechsel und Herz 2019, 28

Monografien und Buchkapitel

1. **Lehmann R.**
Bedeutung der körperlichen Aktivität für die Behandlung des Typ 2 Diabetes mellitus
Diabetes Probleme im Alltag 1996, 12, 5-21
2. **Lehmann R.**
Pankreas- oder Inseltransplantation für Typ 1 Diabetiker – eine Alternative zur intensivierten
Insulintherapie?
Diabetes Probleme im Alltag 1998, 23, 5-21
3. **Lehmann R.** Chapter 3.10 Metabolisches Syndrom in Atheroskleroseprävention: Diagnostik und
Therapie von kardiovaskulären Risikofaktoren, Editors: Battegay E., Nosedà G., Riesen W.F., Verlag
Hans Huber, Bern, 1st edition 2007
4. **Lehmann R**, Steffel J, Lüscher TF
Chapter 5 Diabetes mellitus und metabolisches Syndrom-kardiovaskuläre Implikationen in
Herz-Kreislauf 2. Auflage Editors: Steffel and Lüscher, Verlag Springer 2014
5. **Lehmann R.**
Chapters: Die Leitlinien der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie,
Betreuungsprogramme in der Schweiz, Diabetes mellitus und Schwangerschaft
Gegenwart und Zukunft des β -Zellersatzes bei Typ 1 Diabetes mellitus
2014, 5th edition, Springer Verlag, Editors: Schatz H., Pfeiffer A.F.H.

6. **R. Lehmann** (Redaktion und Autor)
Beta-Zell Ersatz Therapie, Kapitel Einführung 534-537
Diabetologie 2015, 11, 534-79
7. P.A. Gerber, **R. Lehmann**
Inseltransplantation zur Behandlung des Diabetes mellitus Typ 1
Diabetologie 2015, 11: 545-52
8. **R. Lehmann**
Simultaneous islet-kidney and islet-after-kidney transplantation, chapter in
Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas Volume 1
Publisher Elsevier 2019

